Treatment-resistant depression (TRD) stands as a formidable challenge in the realm of mental health, casting a shadow of long-term disability across the globe. At Clinical Outcomes Solutions (COS), we are committed to shedding light on this pressing issue, and our recent research breakthrough has brought us one step closer to effective management.

In a groundbreaking study, our CEO Stacie Hudgens and Senior Director Lysbeth Floden have co-authored an illuminating article titled "Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant." Published on April 20th, 2022, this research serves as a beacon of hope for individuals battling the intricate challenges of TRD.

The research not only underscores the gravity of TRD but also highlights the efficacy of esketamine nasal spray in combination with a new oral antidepressant. The Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) were meticulously examined, offering insights into individual item evaluation and paving the way for a more tailored approach to TRD management.

This publication stands as a testament to COS's unwavering dedication to advancing mental health research. Our commitment to exploring innovative solutions and contributing to the scientific community fuels our drive to transform the lives of those grappling with TRD.

As we navigate the complexities of mental health, this research journey marks a significant stride forward. Stay tuned for more updates on our relentless pursuit of improved treatment modalities and better outcomes for individuals worldwide. Together, we illuminate the path toward a brighter future in mental health management.